The Patent Finder

Bio-Techne Corporation

18 patents currently held · Updated Nov 15, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

2
Ending by 2030
Jul 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 16, 2026
    The maintenance fee for Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy (US 11,649,285) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
  • 1 fee due Feb 4, 2027
    The maintenance fee for Sulfotransferase assay (US 9,096,888) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
  • 1 fee due Apr 17, 2027
    The maintenance fee for Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using (US 11,787,857) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 2 fees due Aug 6 to 13, 2027 · next Aug 6
  • 2 fees due Nov 5, 2027

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,855,051Mycoplasma detection method and composition
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,410,182Phosphatase coupled glycosyltransferase assay
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,096,888Sulfotransferase assay
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,815,529Sulfotransferase assay
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,410,183Methods and kits for detection of O-GlcNAc and N-GlcNAc modification of peptides and proteins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,214,833Profiling Microvesicle Nucleic Acids and Uses Thereof as Signatures in Diagnosis of Renal Transplant Rejection
In force
 · High confidence
In forceHigh confidence
US 10,640,275Dual chamber storage device
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,640,276Dual chamber storage device
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,524,985IL-37 Fusion Protein and Methods of Making and Using Same
In force
 · High confidence
In forceHigh confidence
US 10,752,689Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 3 patents in force now held by others · 7 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 3 abandoned · 7 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited